Preladenant

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Preladenant
Preladenant.svg
Systematic (IUPAC) name
2-(2-Furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine
Clinical data
Legal status
  • Investigational
Routes of
administration		 Oral
Identifiers
CAS Number 377727-87-2 N
ATC code none
PubChem CID: 10117987
IUPHAR/BPS 5614
ChemSpider 8293510
UNII 950O97NUPO N
Chemical data
Formula C25H29N9O3
Molecular mass 503.555 g/mol
  • COCCOc(cc4)ccc4N(CC3)CCN3CCn(c2nc1N)ncc2c(n5)n1nc5-c6occc6
  • InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29) N
  • Key:DTYWJKSSUANMHD-UHFFFAOYSA-N N
 NYesY (what is this?)  (verify)

Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease.[1] Positive results were reported in Phase II clinical trials in humans,[2] but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.[3]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ http://bigstory.ap.org/article/merck-ends-development-parkinsons-disease-drug
Retrieved from "https://infogalactic.com/w/index.php?title=Preladenant&oldid=688341023"